Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 364

Results For "MED"

7107 News Found

Granules India posts Q1 FY24 revenue from operations at Rs. 985.5 Cr
News | August 10, 2023

Granules India posts Q1 FY24 revenue from operations at Rs. 985.5 Cr

API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24


Mandaviya addresses BRICS Health Minister’s meeting
News | August 09, 2023

Mandaviya addresses BRICS Health Minister’s meeting

Reiterates India’s commitment to the BRICS TB Research Network Initiative


Brenntag partners with Qualifyze to enhance pharma audit offering
News | August 09, 2023

Brenntag partners with Qualifyze to enhance pharma audit offering

Qualifyze specializes in Good Practice audits (GxP) audits and covers a wide range of areas, including excipients, starting materials, packaging, sustainability


Govt. passes National Dental Commission Bill, 2023
Policy | August 09, 2023

Govt. passes National Dental Commission Bill, 2023

The National Dental Commission Act 2023, will introduce a groundbreaking regulatory framework by establishing the National Dental Commission


Parliament passes National Nursing and Midwifery Commission (NNMC) Bill, 2023
Policy | August 09, 2023

Parliament passes National Nursing and Midwifery Commission (NNMC) Bill, 2023

Several crucial provisions to elevate the standards of nursing education and services, enhance professional conduct, and ensure greater transparency and accountability introduced


KIMS posts Q1 FY24 consolidated PAT at Rs. 80.81 Cr
News | August 08, 2023

KIMS posts Q1 FY24 consolidated PAT at Rs. 80.81 Cr

KIMS has reported total income of Rs. 609.14 crores during the period ended June 30, 2023


Tatva Chintan Pharma Chem posts Q1 FY24 consolidated PAT at Rs. 9.50 Cr
News | August 06, 2023

Tatva Chintan Pharma Chem posts Q1 FY24 consolidated PAT at Rs. 9.50 Cr

The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023


USFDA approves Merck’s ERVEBO for use in children 12 months of age and older
Drug Approval | August 05, 2023

USFDA approves Merck’s ERVEBO for use in children 12 months of age and older

Merck continues progress in helping to protect people at risk of Zaire ebolavirus disease